+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ulcerative Colitis - Pipeline Review, H2 2018

  • ID: 4667484
  • Drug Pipelines
  • 542 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • 4D Pharma PLC
  • Arena Pharmaceuticals Inc
  • ChironWells GmbH
  • GlaxoSmithKline Plc
  • LG Chem Ltd
  • Pharmaxis Ltd
  • MORE
Ulcerative Colitis - Pipeline Review, H2 2018

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2018, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 16, 41, 33, 56 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4D Pharma PLC
  • Arena Pharmaceuticals Inc
  • ChironWells GmbH
  • GlaxoSmithKline Plc
  • LG Chem Ltd
  • Pharmaxis Ltd
  • MORE
Introduction

Ulcerative Colitis - Overview

Ulcerative Colitis - Therapeutics Development

Ulcerative Colitis - Therapeutics Assessment

Ulcerative Colitis - Companies Involved in Therapeutics Development

Ulcerative Colitis - Drug Profiles

Ulcerative Colitis - Dormant Projects

Ulcerative Colitis - Discontinued Products

Ulcerative Colitis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Ulcerative Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ulcerative Colitis - Pipeline by 4D Pharma PLC, H2 2018

Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2018

Ulcerative Colitis - Pipeline by AbGenomics International Inc, H2 2018

Ulcerative Colitis - Pipeline by Abivax SA, H2 2018

Ulcerative Colitis - Pipeline by Adello Biologics LLC, H2 2018

Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Allergan Plc, H2 2018

Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2018

Ulcerative Colitis - Pipeline by Alvotech Iceland, H2 2018

Ulcerative Colitis - Pipeline by Am-Pharma BV, H2 2018

Ulcerative Colitis - Pipeline by Amgen Inc, H2 2018

Ulcerative Colitis - Pipeline by Antibe Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H2 2018

Ulcerative Colitis - Pipeline by Artelo Biosciences Inc, H2 2018

Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H2 2018

Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2018

Ulcerative Colitis - Pipeline by Avexegen Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Co, H2 2018

Ulcerative Colitis - Pipeline by Celgene Corp, H2 2018

Ulcerative Colitis - Pipeline by Cellix Bio Pvt Ltd, H2 2018

Ulcerative Colitis - Pipeline by Celltrion Inc, H2 2018

Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H2 2018

Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2018

Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Ulcerative Colitis - Pipeline by Coherus BioSciences Inc, H2 2018

Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Ulcerative Colitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2018

Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H2 2018

Ulcerative Colitis - Pipeline by Eli Lilly and Co, H2 2018

Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2018

Ulcerative Colitis - Pipeline by enGene Inc, H2 2018

Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2018

Ulcerative Colitis - Pipeline by Evelo Biosciences Inc, H2 2018

Ulcerative Colitis - Pipeline by Ferring International Center SA, H2 2018

Ulcerative Colitis - Pipeline by Fresenius SE & Co KGaA, H2 2018

Ulcerative Colitis - Pipeline by Galapagos NV, H2 2018

Ulcerative Colitis - Pipeline by Genentech Inc, H2 2018

List of Figures

Number of Products under Development for Ulcerative Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4D Pharma PLC
  • AbbVie Inc
  • AbGenomics International Inc
  • Abivax SA
  • Adello Biologics LLC
  • Akebia Therapeutics Inc
  • Allergan Plc
  • Alpha Cancer Technologies Inc
  • Alvotech Iceland
  • Am-Pharma BV
  • Amgen Inc
  • Antibe Therapeutics Inc
  • Aptevo Therapeutics Inc
  • Arena Pharmaceuticals Inc
  • Artelo Biosciences Inc
  • Atlantic Bio Sci LLC
  • Atlantic Healthcare Plc
  • Avexegen Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Cellix Bio Pvt Ltd
  • Celltrion Inc
  • ChemoCentryx Inc
  • ChironWells GmbH
  • Chong Kun Dang Pharmaceutical Corp
  • Coherus BioSciences Inc
  • Cosmo Pharmaceuticals NV
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • EA Pharma Co Ltd
  • Eli Lilly and Co
  • Enceladus Pharmaceuticals BV
  • enGene Inc
  • Enterome Bioscience SA
  • Evelo Biosciences Inc
  • Ferring International Center SA
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Gossamer Bio Inc
  • IB Pharmaceuticals Inc
  • iCo Therapeutics Inc
  • Inception Sciences Inc
  • Incyte Corp
  • InDex Pharmaceuticals Holding AB
  • InSight Biopharmaceuticals Ltd
  • Intas Pharmaceuticals Ltd
  • Istesso Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Kaken Pharmaceutical Co Ltd
  • Keystone Biologics Inc
  • Kyowa Hakko Kirin Co Ltd
  • LG Chem Ltd
  • LIPID THERAPEUTICS GmbH
  • Lycera Corp
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corp
  • Nash Pharmaceuticals Inc
  • Nextbiotix SAS
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nyrada Inc
  • Ogeda SA
  • OSE Immunotherapeutics
  • Palatin Technologies Inc
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Pharmaxis Ltd
  • Protab Ltd
  • Protagonist Therapeutics Inc
  • Protalix BioTherapeutics Inc
  • Qu Biologics Inc
  • Re-Pharm Ltd
  • RedHill Biopharma Ltd
  • Reliance Life Sciences Pvt Ltd
  • Sandoz International GmbH
  • Sareum Holdings Plc
  • Seres Therapeutics Inc
  • Shire Plc
  • sterna biologicals Gmbh & Co KG
  • Sublimity Therapeutics Ltd
  • Swedish Orphan Biovitrum AB
  • Synedgen Inc
  • Synergy Pharmaceuticals Inc
  • Synlogic Inc
  • Takeda Pharmaceutical Co Ltd
  • Theravance Biopharma Inc
  • Thetis Pharmaceuticals LLC
  • Tillotts Pharma AG
  • TopiVert Ltd
  • Ventria Bioscience
  • Vivelix Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll